News Related to IQVIA

Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO

Aug 17, 2026

Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.

Lawmakers Probe Drugmakers Over China Clinical Trials as U.S. Seeks to Counter Biotech Rise

Jul 31, 2026

Lawmakers opened national security probes into Merck, AbbVie and others over China drug trials. A survey finds China closing in on U.S. biotech leadership, and HHS launched clinical trial reforms to counter the rise.

AI Transforms Clinical Trial Design and Decentralized Trials, But Recruitment Challenges Persist

Jul 01, 2026

AI is transforming decentralized clinical trials, with over $650 million in recent funding and threefold faster patient recruitment. Experts warn that AI-optimized protocols may still struggle to recruit patients, emphasizing lean trial design and adaptive planning.

Proposed 2027 Insurance Rule Omits Copay Assistance Protections, Advocates Warn

Jul 30, 2026

The Trump administration’s proposed 2027 insurance regulation omits copay accumulator protections, allowing insurers and PBMs to continue diverting billions in manufacturer copay assistance from patients. Advocates warn that without action, rising out-of-pocket costs will further strain patients. The rule also fails to close a loophole for large group plans regarding essential health benefits.

Global Drugmakers Expand Rare Disease Research Investment in Brazil Amid Persistent Funding Gaps

Jun 09, 2026

Global drugmakers are expanding rare disease research investment in Brazil, attracted by new regulations, genetic diversity, and the public healthcare system's data capabilities. Major companies including AstraZeneca, Biogen, and Roche have committed significant clinical research budgets to the country. Despite this progress, advocates warn that a significant global funding gap persists, with 95% of rare diseases still lacking an FDA-approved treatment.

BMS CELMoD Mezigdomide Doubles PFS in Myeloma as FDA Reviews Iberdomide

May 29, 2026

BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.

AI's Mixed Impact on Pharma: Accelerating Drug Development While Facing Clinical Trial Realities

Apr 01, 2026

AI could compress drug development from 10-15 years to as little as six years, accelerating discovery and reducing late-stage trial failures. However, clinical trial execution remains heavily dependent on human oversight, with AI estimated to cut costs only 10-15% while facing regulatory and liability constraints. Major pharma companies like Gilead are investing in AI research centers despite practical limitations in trial implementation.

Global Generic Drugs Market Reaches $389 Billion, Poised for Growth to $675 Billion by 2033

Mar 23, 2026

The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.

Pharmaceutical Industry Shifts to Fewer, Larger AI-Driven Drug Development Partnerships

Mar 19, 2026

Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.

Medicus Pharma Reports Phase 2 Results for SkinJect, FDA Clears Teverelix Trial

Mar 05, 2026

Medicus Pharma reported Phase 2 SKNJCT-003 topline data showing 73% clinical clearance and 40% histological clearance at Day 57 in the 200μg cohort. Separately, the FDA cleared the company to begin a Phase 2b dose optimization study for Teverelix in advanced prostate cancer.

Novo Nordisk Expands Ireland Facility, Launches Vials to Counter Eli Lilly in Weight-Loss Market

Feb 13, 2026

Novo Nordisk plans to expand its Athlone facility in Ireland to produce Wegovy for non-US markets and will launch lower-cost vials in the US in 2026, responding to aggressive pricing from Eli Lilly as the company forecasts a 5-13% decline in revenue and operating profit.

Eli Lilly Builds $1.5 Billion Orforglipron Stockpile Ahead of April FDA Decision

Feb 13, 2026

Eli Lilly has accumulated $1.5 billion in pre-launch inventory of its experimental oral weight-loss drug orforglipron ahead of an expected FDA decision in April, up from $550 million last year.

FDA Approves Denosumab Biosimilars and Issues Hypocalcemia Safety Guidance

Dec 22, 2025

The FDA approved multiple denosumab biosimilars in late 2025 and issued REMS safety updates emphasizing severe hypocalcemia risk in patients with advanced chronic kidney disease, including reported hospitalizations and fatalities.